{"disease":{"id":"treatment-of-major-depressive-disorder","name":"Treatment of major depressive disorder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chembl-chembl894","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUPROPION","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"ly4064809","indication_name":"Treatment of major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ly4064809","generic_name":"ly4064809","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":32,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"bupropion-sr-150mg-bid","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupropion SR 150mg bid","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Atypical antidepressant, Norepinephrine-dopamine reuptake inhibitor (NDRI)","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of major depressive disorder in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03968159","title":"Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04000009","title":"Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04103892","title":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Clexio Biosciences Ltd.","has_results":true},{"nct_id":"NCT06340958","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Clexio Biosciences Ltd.","has_results":false},{"nct_id":"NCT06511908","title":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}